Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007
BMC Infectious Diseases volume 10, Article number: 109 (2010)
Since 2003, the Global Fund has supported the scale-up of HIV/AIDS, tuberculosis and malaria control in low- and middle-income countries. This paper presents and discusses a methodology for estimating the lives saved through selected service deliveries reported to the Global Fund.
Global Fund-supported programs reported, by end-2007, 1.4 million HIV-infected persons on antiretroviral treatment (ARV), 3.3 million new smear-positive tuberculosis cases detected in DOTS (directly observed TB treatment, short course) programs, and 46 million insecticide-treated mosquito nets (ITNs) delivered. We estimated the corresponding lives saved using adaptations of existing epidemiological estimation models.
By end-2007, an estimated 681,000 lives (95% uncertainty range 619,000-774,000) were saved and 1,097,000 (993,000-1,249,000) life-years gained by ARV. DOTS treatment would have saved 1.63 million lives (1.09 - 2.17 million) when compared against no treatment, or 408,000 lives (265,000-551,000) when compared against non-DOTS treatment. ITN distributions in countries with stable endemic falciparum malaria were estimated to have achieved protection from malaria for 26 million of child-years at risk cumulatively, resulting in 130,000 (27,000-232,000) under-5 deaths prevented.
These results illustrate the scale of mortality effects that supported programs may have achieved in recent years, despite margins of uncertainty and covering only selected intervention components. Evidence-based evaluation of disease impact of the programs supported by the Global Fund with international and in-country partners must be strengthened using population-level data on intervention coverage and demographic outcomes, information on quality of services, and trends in disease burdens recorded in national health information systems.
Only in some five years, the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) has become a major player in international health development. In 2005, the Global Fund provided 21% of international funding for HIV/AIDS programs in low- and middle-income countries, 67% for tuberculosis (TB), and 64% for malaria. By December 2007, it has approved a total of US$ 10.1 billion proposals, in more than 550 grants in 136 countries, of which US$ 4.8 billion had been disbursed to recipients in 134 countries. As control effort of the three diseases is scaled up, there is now considerable interest to show the scale of health benefits from interventions supported.
For evaluation of disease impact, Global Fund recipients collect epidemiological data on relevant changes in mortality and morbidity. Given the nature of the diseases and interventions and data collection mechanisms, it may take several years before impact becomes detectable. For example, reductions in new HIV infections are inferred retrospectively from prevalence trends over preceding years. WHO and UNAIDS regularly publish regional-level HIV incidence and prevalence estimates, using country surveillance and survey data that often require two years to be released [3–7]. Similarly, all-cause under-five mortality, a key impact indicator for malaria in areas of high endemicity, is often measured in population-based surveys with 3-5 year intervals. Malaria-related mortality reductions become apparent only 3-5 years after they start, with the 'birth history' method. The consensus TB estimation model, applied to high-burden countries by WHO with national TB programs[10, 11], relies on patient cohort data about treatment outcomes from two preceding years.
In view of these data limitations, it is still early for the impact of Global Fund support to be fully measured. As an interim approach, we estimated the scale of lives saved, by summarizing deaths averted from key service delivery results reported by recipient programs. Interventions considered are antiretroviral treatment (ARV), Directly Observed TB Treatment, short-course (DOTS) and insecticide-treated mosquito nets (ITN). Estimates of their efficacies against mortality are available[7, 12–17]. This paper presents and discusses the methodology for this approach with estimates of lives saved through service deliveries reported to the Global Fund between 2003 and end-2007.
Lives saved and, for ARV, life-years gained, were estimated using mortality estimation models and assumptions used by UNAIDS, WHO Stop TB and Roll Back Malaria. Models were adapted to use as main input service delivery results available from recipient countries (Table 1 and below).
Service delivery results
Supported programs regularly report progress against targets on standardized indicatorshttp://www.theglobalfund.org, as the basis for performance-based funding. Reported results are verified by independent contractors. The Global Fund secretariat then aggregates grant delivery results across the portfolio, for reporting back to donors[20, 21] (Table 2). For ARV, the validity and extent of overlap are assessed with WHO and the US President's Emergency Program for AIDS Relief (PEPFAR), resulting in harmonized numbers[22–24]. Results from multi-country grants were excluded for simplicity.
AIDS mortality averted due to ARV
ARV programs routinely report to the Global Fund (and other international organizations) on people currently on ARV. This indicator forms a key input to the epidemiological modelling package (known as Spectrum) that the UNAIDS Reference Group on Estimates, Modelling, and Projections recommends for calculating lives saved and life-years gained by ARV. Life-years gained is the preferred metric for population survival benefit, because ARV extends life but does not cure infections.
Spectrum uses demographic data and estimates of country HIV prevalence, incidence, mortality and ARV coverage rates over time, to estimate epidemic trends in the presence and (hypothetical) absence of ARV in each country[24, 26]. Spectrum assumes that all ARV is provided to HIV-infected people in need of such treatment, which is operationalized as a median of 3 years before estimated time of AIDS-related deaths. Survival at 12 months on ARV is assumed to be 85% for both adults and children, after which each next year 5% of survivors would die. People reported on treatment in 2004, 2005 or 2006 were assumed to have started in the respective years and stayed on treatment through end-2007, unless they had died. In a comparison scenario, annual mortality was assumed to be 50% by 12 months, and 100% by 24 months from starting to need ARV for people not accessing the treatment. 'Lives saved' by 2007 were calculated as the difference between cumulative numbers of deaths with and without ARV.
These projections yielded average ratios of 'life-years gained per patient-year of ARV', and 'lives saved per patient on ARV', which varied among countries and over calendar years according to varying stages of disease that patients initiated ARV, indirect demographic effects (restored fertility etc.), and dynamic effects of ARV, through reduced viral load, on reducing HIV transmission. To subsequently obtain mortality effect estimates, the regionally averaged ratios of 'life-years gained per patient-year of ARV' over the period 2003-2007, and of 'lives saved per patient on ARV' at end-2007 were applied to regionally summed ARV numbers reported by Global Fund recipients at end-2007.
TB mortality averted due to DOTS
We estimated TB mortality based on numbers of new smear-positive case detections in supported DOTS programs and TB case fatality rates. For a few programs reporting case detections without specifying the smear status, we assumed that 50% of cases were smear-positive. All cases were assumed to start DOTS without delay. Because of the long duration of TB treatment, we considered half of cases detected in each calendar year to contribute to lives saved in that year, counting the other half as savings during the next year (Table 1).
For DOTS, two comparison scenarios were considered. The simplest comparison, consistent with the 'no intervention' counterfactual scenario for ARV and ITNs, was against no treatment. The alternative is against non-DOTS treatment, which is commonly used in TB impact evaluations[12, 27], as DOTS programs provide better treatment to patients who would otherwise have been treated in sub-standard ways. While not always clearing infection and stopping transmission, non-DOTS treatment still often prevents the patient from dying.
Case fatality rates for DOTS, non-DOTS and no treatment scenarios were available from WHO, stratified by HIV and smear status. These country-specific rates were combined with country-specific proportions of DOTS-treated smear-positive TB cases that are HIV-positive, for the year 2006.
Malaria-related mortality averted due to ITNs
In areas of sub-Saharan Africa with stable endemic falciparum malaria, effective use of ITNs results in averting 5.5 under-five deaths per 1000 children protected per year (Table 1). This efficacy was applied to estimate mortality reductions resulting from ITN deliveries in recipient programs in sub-Saharan Africa and in Papua New Guinea, where falciparum malaria occurs of a similar endemicity. Mortality among adults, from non-falciparum malaria and in places with non-stable falciparum malaria was not estimated, due to limited evidence of intervention effectiveness and lack of reliable estimates of populations at risk.
We assumed that each ITN distributed resulted in an average of 1.1 child-year of protection, over the lifetime of the net. This assumption was based on:
• A median ratio of 0.73 between the proportion of households possessing one or more ITNs and the proportion of children under-5 that sleep under an ITN. This was the ratio observed across 37 DHS and MICS surveys conducted in malaria-endemic countries between 2000 and 2006;
• An effective ITN lifespan of 1.5 years. This takes into account that some Global Fund-supported malaria programs also supported ITN re-impregnations.
• 0.73 * 1.5 = 1.1.
The cumulative years of protection achieved per ITN up to the date was calculated from the dates of ITN distributions in each country: ITNs distributed before end-2006 were counted as having been used for 1.5 years, and ITNs distributed in 2007 counted for 0.5 years (see also Table 2 and Additional file 1, Online Appendix).
95% uncertainty ranges (UR's) were calculated applying the delta method to the calculation of averted deaths, keeping only first-order terms in the error expression and combining 95% UR's of all input parameters (see Table 1).
For service delivery results, on-site verification had revealed that in 2005-6 83% of country reports were within a 20% margin, without systematic bias in either direction (over-reporting or under-reporting). We therefore assumed a 25% error on each country delivery result, without dependency among countries.
For other parameters, errors were (conservatively) assumed to be systematic rather than country-specific. When summing lives saved across the 3 diseases, errors in disease-specific estimates were taken as independent.
As of end-2007, 1.44 million people were reported to be on ARV, in 91 supported HIV programs (Table 3). The resulting number of life-years gained was 1,097,000 (95% uncertainty range 993,000-1,249,000). With the 1.44 million patients alive, 108,000 were estimated to have died by end-2007, whereas, had ARV not been provided, 782,000 would have died. An estimated 681,000 deaths (619,000-774,000) were averted, or 681,000 lives saved, due to ARV scale-up by end-2007 (Figure 1).
Supported TB programs in 68 countries reported a cumulative 3.3 million smear-positive TB case detections by end-2007 (Table 4). Out of these, 272,000 were estimated to have died in spite of DOTS. Using 'without-treatment' as comparison scenario, deaths would have amounted to 1.9 million, resulting in an estimated 1.63 million lives saved (1.09 - 2.17 million). Under non-DOTS treatment, by contrast, 680,000 smear-positive cases would have died, corresponding to an estimated 408,000 lives saved (265,000-551,000) (Figure 1).
By December 2007, 46 million ITNs had been distributed across 62 countries. Over 38 million ITNs were distributed in 35 African countries with stable endemic falciparum malaria; 231,000 in Papua New Guinea, and 7.4 million in lower-endemic areas (Table 5).
Across sub-Saharan Africa and Papua New Guinea, the average duration of past usage of ITNs distributed was 0.89 years by end-2007, resulting in a cumulative total of nearly 26 million of child-years of protection by end-2007 (Table 5).
These 36 countries had around 3.8 million under-5 deaths in 2006. Against this baseline, we estimated that Global Fund-supported ITNs had averted 130,000 deaths (27,000-232,000) up to end-2007 (Figure 1).
Total lives saved
Adding the estimated lives saved from ARV, DOTS and ITN, without adjustment for interactions between diseases or the possibility of persons benefiting from multiple interventions, total lives saved by Global Fund-supported programs would stand at around 2.44 million (1.74-3.18 million) by December 2007. Alternatively, when using non-DOTS treatment as comparison (instead of no treatment), lives saved sum to 1.22 million (911,000-1,557,000).
The presented estimates of lives saved and life-years gained by Global Fund-supported ARV, DOTS and ITNs indicate the magnitude of mortality reductions achieved by recipient programs. While not being an actual measurement or formal evaluation of program impact, the estimations allow the Global Fund to gauge progress as service delivery reports from programs accumulate.
The estimates do not reflect the whole spectrum of interventions supported. Notably, HIV infections averted by prevention services will in future save lives from AIDS, but cannot readily be estimated from routine delivery reports. Effective HIV prevention often results from a multi-sectoral package of services[33–36], and infections prevented for a given level of intervention coverage vary among countries depending on local HIV incidence rates and transmission modes. Methods to estimate HIV infections averted need urgent development.
For malaria, artemisinin-based combination treatments (ACTs) probably have important mortality effects. By December 2007, Global Fund-supported programs had delivered over 24 million ACT courses, across 49 countries. The effectiveness of ACTs against mortality has not been established through randomized trials and will depend on the timeliness of and compliance with treatment; proportions of ACTs for true malaria episodes (rather than misused for non-malarial fevers); possible effects of ACTs on preventing repeat episodes due to recrudescent infection; and the comparison scenario (no treatment or ineffective mono-therapy). The presented model furthermore excluded indoor residual spraying (IRS). As more knowledge becomes available, ACT and IRS should be included in lives saved estimation.
The gap-filling nature of Global Fund financing makes it difficult to define a specific contribution as distinct from other donors and (pre-)existing in-country efforts. Some programs, particularly HIV and TB, report program-wide results covering all contributions from multiple domestic and international funding sources to the Global Fund, which promotes program supports rather than a project approach. Lives saved result from collective efforts of in-country programs, to which the Global Fund contributes alongside other partners. For malaria, on the other hand, total service deliveries covering all partners' contributions considerably outnumber results reported to the Global Fund: e.g. in 2006 alone, 63 million ITNs were produced worldwide. For ARV, the 1,439,000 life-years saved represents around 33% of a total 3.2 million estimated life-years saved in low- and middle-income countries by end-2007. The 33% share is somewhat less than approximately 50% share in ARV results (a total of 2.9 million as of end-2007), because some large ARV programs with support from Global Fund (e.g., Brazil) had provided people on ARV much longer, with larger effects.
Several limitations and caveats concerning input data and assumptions must be acknowledged. Errors may occur at any stages. Misclassification of smear positivity for TB is one example. While service delivery numbers may be imprecise and performance-based funding may provide incentives for over-reporting, the errors are not systematically in one direction, so that aggregated portfolio results should roughly reflect what was delivered. In reality, results at mid- and end-year released by the Global Fund secretariat are significantly conservative because results always have reporting delays but only actual results available at the time of data compilation are aggregated without projecting to release dates. Aggregation at country level is done also in a conservative manner to avoid double counting. Data quality issues nevertheless highlight an urgent need to strengthen national monitoring and health information systems.
The presented methodology was designed exclusively to produce a portfolio-aggregate indication of global-level health gain, although we used certain country-specific input assumptions and presented estimates by regional break-down. Country-specific evaluations would, in contrast, require more refined methods and inputs.
The largest uncertainties in these estimates lie in the epidemiological models and their basic (cross-country) assumptions. The 2007 UNAIDS model for estimating HIV-related deaths may be possibly optimistic in assuming 5-15% annual mortality on ARV, since cohort studies in resource-poor settings found up to 27% mortality within the first year, and substantial losses to follow-up which may include some additional mortality[38, 39]. Given that ARV reporting to Global Fund does not include an explicit dimension of treatment quality or patient retention, some proportion of treatments delivered are likely to be of less good quality and clinical outcome than is typical in western settings or in research cohorts in resource-poor settings.
For TB, lives saved depend critically on the comparison scenario (Figure 1). While a simplistic comparison against 'no-treatment' is most consistent across the services studied, this scenario may be less appropriate for DOTS (compared to ARV and ITNs), given the relatively high effectiveness and potential availability of non-DOTS treatment[12, 27, 28]. The purpose of the paper is to indicate the overall scale of programs rather than additional impact due to scale-ups.
Our estimate of lives saved by Global Fund-supported ITNs depends critically on assumptions to convert ITN deliveries into child-years of protection. The assumption that each ITN distributed provides an average 1.1 child-year of protection (see Methods) is simplistic and probably conservative, because: (i) some 38% of ITNs distributions reported by supported programs were long-lasting insecticidal nets (LLINs) that remain effective throughout their lifetime of typically 3-4 years; (ii) even for conventional ITNs, the assumed 1.5-year lifespan may be short in view of insecticide re-impregnations supported through Global Fund grants, and (iii) ITN usage was estimated based on 2000-06 surveys, but increased funds also support behavior change communication activities. Estimates of child protection by ITNs should be validated and improved based on country-specific coverage data, forthcoming from household surveys in many recipient countries. Since recent surveys demonstrated significant increases in ITN usage among under-fives[31, 42], lives saved from malaria are expected to increase rapidly over the coming years.
There is reasonable consensus about the efficacy of ITNs against mortality in children exposed to endemic falciparum malaria, for given levels of coverage, in all recent malaria impact models, including a consensus model under development by UNICEF and WHO. Malaria effect estimates were, nonetheless, conservative because we did not consider mortality averted outside sub-Saharan Africa and Papua New Guinea. In any case, considerable uncertainties about the size and geographical distribution of populations exposed to stable endemic malaria contribute to relatively wide uncertainty ranges, compared to ARV and DOTS (error bars in Figure 1).
The presented uncertainty ranges, particularly for ARV and DOTS, may be minimum intervals, which do not capture the complex chain of factors that intervene between service delivery counts, population coverage and impact, such as quality of services including (mis-)diagnosis, drug quality, patient counselling and support to promote patient retention and treatment adherence. Periodic evaluation of quality of services must therefore be added to program progress tracking and performance evaluation.
Longer-term, improved approaches to measuring disease impact are essential in low- and middle-income countries. To enable this and to evaluate its institutional performance and partners context, the Global Fund recommends that programs spend 5-10% of grant budgets on strengthening monitoring and evaluation systems as well as supporting vital registration. Furthermore, the Global Fund Board has commissioned an independent Five-Year Evaluation including impact evaluations reinforcing quality data collection and analysis in 20 countries[20, 44].
The presented estimates indicate the scale of mortality effects that Global Fund-supported programs may have achieved over recent years. While the numbers carry great margins of uncertainty and cover only selected program components, they reflect the best information available to date. Evidence-based evaluation of the impact of HIV/AIDS, TB and malaria programs supported by the Global Fund and other partners is ongoing and must be further strengthened to maximize health gain. Great improvements will be made by triangulating service delivery reports with population-level data on intervention coverage and demographic outcomes, information on quality of services, and trends in health facility disease burdens recorded in national health information and management systems.
The Global Fund to Fight AIDS, Tuberculosis and Malaria. Resource needs: Funding the global fight against HIV/AIDS, tuberculosis and malaria. 2007, Geneva, [http://www.theglobalfund.org/en/files/about/replenishment/oslo/Resource%20Needs.pdf]
The Global Fund to Fight AIDS, Tuberculosis and Malaria. Monthly Progress Update - 14 December 2007. Geneva, 14 December, 2007, [http://www.theglobalfund.org/en/media_center/publications/factsheets_faq/default.asp#fact_sheets]
Brown T, Grassly NC, Garnett G, Stanecki K: Improving projections at the country level: the UNAIDS Estimation and Projection Package 2005. Sex Transm Infect. 2006, 82 (Suppl 3): iii34-40. 10.1136/sti.2006.020230.
Lyerla R, Gouws E, Garcia-Calleja JM, Zaniewski E: The 2005 Workbook: an improved tool for estimating HIV prevalence in countries with low level and concentrated epidemics. Sex Transm Infect. 2006, 82 (Suppl 3): iii41-44. 10.1136/sti.2006.020198.
Morgan M, Walker N, Gouws E, Stanecki KA, Stover J: Improved plausibility bounds about the 2005 HIV and AIDS estimates. Sex Transm Infect. 2006, 82 (Suppl 3): iii71-77. 10.1136/sti.2006.021097.
Stover J, Bertozzi S, Gutierrez JP, Walker N, Stanecki KA, Greener R, Gouws E, Hankins C, Garnett GP, Salomon J, Boerma JT, De Lay P, Ghys PD: The global impact of scaling-up HIV/AIDS prevention programs in low- and middle-income countries. Science. 2006, 311: 1474-6.
UNAIDS, World Health Organization: AIDS epidemic update, December 2006. 2006, Geneva, [http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf]
ORC Macro - MEASURE DHS+. Demographic and Health Surveys (DHS). ORC Macro, Calverton, MD, USA, [http://www.measuredhs.com]
Korenromp EL, Arnold F, Williams BG, Nahlen B, Snow RW: Monitoring trends in under-five mortality rates through national birth history surveys. Int J Epid. 2004, 33: 1293-301. 10.1093/ije/dyh182.
Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Jama. 2005, 293: 2767-75. 10.1001/jama.293.22.2767.
World Health Organization: Global Tuberculosis Control: surveillance, planning, financing. WHO report 2007. 2007, World Health Organization, Geneva, [http://www.who.int/tb/publications/global_report/en/index.html]
Dye C, Fengzeng Z, Scheele S, Williams B: Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol. 2000, 29: 558-64. 10.1093/ije/29.3.558.
Hanson K, Kikumbih N, Armstrong Schellenberg J, Mponda H, Nathan R, Lake S, Mills A, Tanner M, Lengeler C: Cost-effectiveness of social marketing of insecticide-treated nets for malaria control in the United Republic of Tanzania. Bull World Health Organ. 2003, 81: 269-76.
Yukich J, Tediosi F, Lengeler C: Operations, costs and cost-effectiveness of five ITN programs (Eritrea, Malawi, Tanzania, Togo, Senegal) and two IRS programs (Kwa-Zulu Natal, Mozambique). 2007, Swiss Tropical Institute, Basel, 12 July (final draft), [http://www.rollbackmalaria.org/partnership/wg/wg_itn/docs/Yukich2007.pdf]
Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA: Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Bmj. 2005, 331 (7530): 1431-7. 10.1136/bmj.38643.368692.68.
Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP: Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. Aids. 2007, 21 (Suppl 4): S117-28. 10.1097/01.aids.0000279714.60935.a2.
Bachmann MO: Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. AIDS Care. 2006, 18: 109-20. 10.1080/09540120500159334.
Global Fund to Fight AIDS, Tuberculosis, and Malaria. Monitoring and evaluation toolkit: HIV/AIDS, tuberculosis, and malaria. 2006, Geneva: Global Fund to Fight AIDS, Tuberculosis, and Malaria, [http://www.theglobalfund.org/en/files/about/replenishment/resource_needs_2006.pdf]second
Low-Beer D, Afkhami H, Komatsu R, Banati P, Sempala M, Katz I, Cutler J, Schumacher P, Tran-Ba-Huy R, Schwartlander B: Making performance-based funding work for health. PLoS Med. 2007, 4: e219-10.1371/journal.pmed.0040219.
The Global Fund to Fight AIDS, Tuberculosis and Malaria. Partners in impact: Results report. 2007, The Global Fund to fight AIDS, Tuberculosis, and Malaria, Geneva, [http://www.theglobalfund.org/en/files/about/replenishment/oslo/Progress%20Report.pdf]
Komatsu R, Low-Beer D, Schwartlander B: Global Fund-supported programmes contribution to international targets and the Millennium Development Goals: an initial analysis. Bull World Health Organ. 2007, 85: 805-11. 10.2471/BLT.06.038315.
Boerma JT, Stanecki KA, Newell ML, Luo C, Beusenberg M, Garnett GP, Little K, Calleja JG, Crowley S, Kim JY, Zaniewski E, Walker N, Stover J, Ghys PD: Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ. 2006, 84: 145-50. 10.2471/BLT.05.025189.
World Health Organization, UNAIDS: Progress on global access to HIV antiretroviral therapy. A report on '3 by 5' and beyond. 2006, World Health Organization, UNAIDS, Geneva, [http://www.who.int/hiv/fullreport_en_highres.pdf]
World Health Organization, UNAIDS, and UNICEF: Towards Universal Access: Scaling-up priority HIV/AIDS interventions in the health sector. Progress report 2008. 2008, Geneva, [http://www.who.int/hiv/pub/Towards_Universal_Access_Report_2008.pdf]
UNAIDS Reference Group on Estimates, Modelling, and Projections: Methods for estimation of ART's impact on deaths averted/delayed; and Developments in Estimation and Projection Package (EPP) 2007. Technical report and recommendations. 2007, UNAIDS, Baltimore, http://data.unaids.org/pub/InformationNote/2007/new_evidence_survival_2007_en.pdf, [http://www.epidem.org/Publications/Baltimore2007_13July.pdf] http://www.epidem.org/Publications/Baltimore2007_13July.pdf
UNAIDS: Epidemiological software and tools: Estimation and Projection Package (EPP) and Spectrum model. Accessed 20th May, 2008, [http://www.unaids.org/en/KnowledgeCentre/HIVData/Epidemiology/epi_software2007.asp]
Suarez PG, Watt CJ, Alarcon E, Portocarrero J, Zavala D, Canales R, Luelmo F, Espinal MA, Dye C: The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001, 184: 473-8. 10.1086/322777.
World Health Organization: Global Tuberculosis Control: surveillance, planning, financing. WHO report 2008. 2008, World Health Organization, Geneva, [http://www.who.int/tb/publications/global_report/en/index.html]
Lengeler C: Insecticide-treated bed nets and curtains for preventing malaria (Cochrane review). 2004, [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15106149]
Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW: The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 2008, 5: e38-10.1371/journal.pmed.0050038.
UNICEF, Roll Back Malaria Partnership: Malaria & children. Progress in intervention coverage. New York. 2007
Oehlert GW: A note on the delta method. American Statistician. 1992, 46: 27-29. 10.2307/2684406.
Kerrigan D, Ellen JM, Moreno L, Rosario S, Katz J, Celentano DD, Sweat M: Environmental-structural factors significantly associated with consistent condom use among female sex workers in the Dominican Republic. AIDS. 2003, 17: 415-23. 10.1097/00002030-200302140-00016.
Merson MH, Dayton JM, O'Reilly K: Effectiveness of HIV prevention interventions in developing countries. AIDS. 2000, 14 (Suppl 2): S68-84.
Morisky DE, Pena M, Tiglao TV, Liu KY: The impact of the work environment on condom use among female bar workers in the Philippines. Health Educ Behav. 2002, 29: 461-72. 10.1177/109019810202900406.
Parker RG, Easton D, Klein CH: Structural barriers and facilitators in HIV prevention: a review of international research. AIDS. 2000, 14 (Suppl 1): S22-32. 10.1097/00002030-200006001-00004.
Heaton LM, Komatsu R, Low-Beer D, Fowler TB, Way PO: Estimating the number of HIV infections averted: an approach and its issues. Sex Transm Infect. 2008, 84 (Suppl 1): i92-i96. 10.1136/sti.2008.030247.
Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006, 367: 817-24. 10.1016/S0140-6736(06)68337-2.
Rosen S, Fox MP, Gill CJ: Patient retention in antiretroviral therapy programs in sub-saharan Africa: a systematic review. PLoS Med. 2007, 4: e298-10.1371/journal.pmed.0040298.
Smith SC, Joshi UB, Grabowsky M, Selanikio J, Nobiya T, Aapore T: Evaluation of bednets after 38 months of household use in northwest Ghana. Am J Trop Med Hyg. 2007, 77: 243-8.
Mulligan JA, Yukich J, Hanson K: Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets. Malar J. 2008, 7: 32-10.1186/1475-2875-7-32.
Miller JM, Korenromp EL, Nahlen BL, Steketee RW: Estimating the number of insecticide-treated nets required by African households to reach continent-wide malaria coverage targets. Jama. 2007, 297: 2241-50. 10.1001/jama.297.20.2241.
Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS: How many child deaths can we prevent this year?. Lancet. 2003, 362: 65-71. 10.1016/S0140-6736(03)13811-1.
Nahlen BL, Low-Beer D: Building to collective impact: the Global Fund support for measuring reduction in the burden of malaria. Am J Trop Med Hyg. 2007, 77: 321-7.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/10/109/prepub
All results and lives saved are because of country programs and partners. We thank Itamar Katz, Donna Lee and Musoke Jackson Sempala for compiling results from countries, and many colleagues for discussion and advice. In particular, we are grateful to Brian Williams for advice and assistance in the calculation of uncertainty ranges, to Richard Cibulskis for comments on the malaria estimations, to Karen Stanecki, Elizabeth Zaniewski, and the UNAIDS/WHO Working Group on Global HIV/AIDS & STI Surveillance and experts of the UNAIDS Reference Group on Estimates, Modelling and Projections for assistance in and discussion on the HIV/AIDS estimations, and to Suzanne Scheele and Peter Ghys for contributions to an earlier draft.
No particular funding was provided to develop this manuscript. The authors declare that they have no competing interests.
RK, EK and DLB designed the study, led the analyses, and developed the manuscript. CD and CW oversaw the TB estimation and contributed to interpretation and writing. EK implemented the malaria estimation, with advise from RS and BN who also contributed to interpretation and writing. RL and JMGC contributed to estimating and interpreting the effects of ARV and to writing. JC and BS conceptualized and contributed to interpretation and writing. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 1: Example calculation of lives saved by ITNs. (a) basic calculation; (b) additional step to correct for 'over 100% child coverage' in selected countries. (DOC 50 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Komatsu, R., Korenromp, E.L., Low-Beer, D. et al. Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis 10, 109 (2010). https://doi.org/10.1186/1471-2334-10-109
- Indoor Residual Spray
- Global Fund
- Comparison Scenario
- Recipient Program